Dr. Reddy’s facility struck by another Form 483

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Aramyan)
(Image: Getty/Aramyan)

Related tags: India, Fda, Form 483

Dr. Reddy’s Bachupally manufacturing plant has received a second Form 483 from the US FDA in the past two years.

The Indian company did not release many details​ regarding the US Food and Drug Administration (FDA)’s findings, only noting that the Hyderabad-based manufacturing plant received 11 observations.

The company stated, “We will address [the observations] comprehensively within the stipulated timeline.”

This is the second time that the formulation manufacturing plant has seen FDA regulatory action at the facility, after it was issued a Form 483 in May 2017​. During the previous inspection that resulted in a Form 483, the agency also found 11 observations, which the company told us, at the time, were ‘mostly procedural’.

The Hyderabad site houses three formulation plants, the most recent inspection relates to ‘plant 3’; the space that also holds the company’s global office, as well as three active pharmaceutical ingredient (API) manufacturing facilities and four R&D sites.

Problems at the site also extended to an API plant, which was issued a Form 483 in March 2018​.

Six months ago, the company sold an API plant​ to the generic joint venture, Therapiva. The company noted the decision to sell was to streamline its business to ‘optimise’ global costs.

Shares in Dr. Reddy’s dipped 4% on the news, dropping from ₹2776 ($39.31) on the release of the news to ₹2663 ($37.71), as of the time of reporting.

Related news

Show more

Related products

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers